#USA #Shareholders #Stock Split #Staten Island #Acurx Pharmaceuticals

Acurx Pharmaceuticals Initiates a Reverse Stock Split

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has recently made headlines with the announcement of a significant corporate decision aimed at increasing its stock value. The biopharmaceutical company, which specializes in developing new antibiotics for challenging bacterial infections, will undertake a 1-for-20 reverse stock split effective as of August 5, 2025. This measure, approved at the Company's annual stockholder meeting, is crucial for the organization to comply with Nasdaq's minimum bid price regulations.

What Does a Reverse Stock Split Mean?

A reverse stock split consolidates the number of existing shares of stock into fewer, proportionally more valuable shares. In this case, for every twenty shares currently held by stockholders, they will receive one new share. This will reduce the total number of shares outstanding from approximately 30.76 million to around 1.54 million while not altering the total authorized amount of shares.

Although the number of shares will decrease, the intent is clear: to boost the per-share stock price, a critical requirement for remaining listed on the Nasdaq Capital Market. The trade of the new shares will commence under a new CUSIP number, 00510M 203, while retaining the existing ticker symbol ACXP.

Implications for Shareholders

For shareholders, this change carries specific implications. Importantly, no fractional shares will exist following the split; if any stockholder would end up with a fraction of a share, they will receive a cash payment equivalent to that fraction's worth based on the previous day's closing price before the split takes effect.

For example, if you held 40 shares before the split, you would end up with 2 shares post-split and receive a cash payment for the value of any fractional shares, thus ensuring that every investor is made whole.

Stockholders holding their shares electronically in book-entry form need not take any action as their records will automatically reflect these changes. Those with physical stock certificates will receive further instructions from the Company’s transfer agent, VStock Transfer, LLC, regarding how to exchange their shares.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals is at the forefront of creating a new class of antibiotics designed to combat infections from Gram-positive bacteria. Their pipeline includes ibezapolstat, aimed at fighting Clostridioides difficile infections and is set for Phase 3 trials. Their innovative approach employs targeted mechanisms that inhibit bacterial replication while minimizing harmful effects on human cells.

As Acurx prepares for the Reverse Split, it simultaneously endeavors to solidify financing and clear regulatory hurdles necessary to advance its clinical trials. The future holds promise, but many moving parts must align for Acurx to realize its full potential in the pharmaceutical landscape.

Conclusion

Overall, this strategic move by Acurx Pharmaceuticals is designed not just to meet regulatory standards but significantly to improve shareholder value. As the effective date of the reverse stock split approaches, the scientific community and investors alike will watch closely how this biopharmaceutical firm navigates its future challenges and opportunities arising in antibiotic development. For continual updates on Acurx and their innovative solutions in healthcare, their official website, acurxpharma.com, will provide valuable insights.

Investors and market analysts will also remain vigilant regarding how this split impacts stock performance and the company's trajectory as it battles to bring impactful antibiotics to market, including potential treatments for critical infections endemic in today's healthcare context.